SG156641A1 - Compounds for nonsense suppression, and methods for their use - Google Patents

Compounds for nonsense suppression, and methods for their use

Info

Publication number: SG156641A1
Authority: SG; Singapore
Prior art keywords: compounds; methods; compositions; present; nonsense suppression
Prior art date: 2004-10-13

Application number

SG200906829-7A

Other languages

English (en)

Inventor

Neil Almstead

Guangming Chen

Gary M Karp

Ellen Welch

Richard Wilde

Jeffrey A Campbell

Original Assignee

Ptc Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-13

Filing date

2005-10-13

Publication date

2009-11-26

2005-10-13 Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc

2009-11-26 Publication of SG156641A1 publication Critical patent/SG156641A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/24—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65306—Five-membered rings containing two nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)

SG200906829-7A 2004-10-13 2005-10-13 Compounds for nonsense suppression, and methods for their use SG156641A1 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US61765504P	2004-10-13	2004-10-13
US61763304P	2004-10-13	2004-10-13
US61767004P	2004-10-13	2004-10-13
US61763404P	2004-10-13	2004-10-13
US61765304P	2004-10-13	2004-10-13
US62417004P	2004-11-03	2004-11-03

Publications (1)

Publication Number	Publication Date
SG156641A1 true SG156641A1 (en)	2009-11-26

Family

ID=35517967

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG200906829-7A SG156641A1 (en)	2004-10-13	2005-10-13	Compounds for nonsense suppression, and methods for their use
SG200906828-9A SG156640A1 (en)	2004-10-13	2005-10-13	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG200906828-9A SG156640A1 (en)	2004-10-13	2005-10-13	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases

Country Status (11)

Country	Link
US (10)	US9315467B2 (fr)
EP (13)	EP2301536B1 (fr)
JP (3)	JP2008515990A (fr)
KR (3)	KR20070067201A (fr)
AU (3)	AU2005295778A1 (fr)
BR (2)	BRPI0515995A (fr)
CA (5)	CA2582885A1 (fr)
IL (3)	IL182464A0 (fr)
MX (3)	MX2007004487A (fr)
SG (2)	SG156641A1 (fr)
WO (5)	WO2006044456A1 (fr)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1543157A4 (fr)	2002-07-24	2006-11-15	Ptc Therapeutics Inc	Methodes destinees a identifier des petites molecules modulant la terminaison de traduction prematuree et la degradation de l'arnm induite par mutation non-sens
US6992096B2 (en)	2003-04-11	2006-01-31	Ptc Therapeutics, Inc.	1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2006044456A1 (fr) *	2004-10-13	2006-04-27	Ptc Therapeutics, Inc.	Composes de suppression de non-sens et procedes de leur utilisation
US20080312303A1 (en) *	2005-10-14	2008-12-18	Neurosearch A/S	Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex
WO2007047706A2 (fr)	2005-10-17	2007-04-26	Children's Hospital	Procedes et compositions de regulation de l'expression genique
DK1986633T3 (da)	2006-02-10	2014-11-03	Summit Corp Plc	Behandling af duchennes muskeldystrofi
SG170819A1 (en) *	2006-03-30	2011-05-30	Ptc Therapeutics Inc	Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
PL2674428T3 (pl)	2006-04-07	2017-01-31	Vertex Pharmaceuticals Incorporated	Modulatory transporterów z kasetą wiążącą ATP
DK2076501T3 (da) *	2006-09-25	2016-02-29	Ptc Therapeutics Inc	Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre
KR100858357B1 (ko) *	2006-10-02	2008-09-11	(주) 디지탈바이오텍	벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
WO2008157407A2 (fr) *	2007-06-13	2008-12-24	University Of Virginia Patent Foundation	Compositions et procédés pour traiter la leucémie
PT2170396T (pt)	2007-08-03	2017-03-31	Summit Corp Plc	Combinação de fármacos para o tratamento da distrofia muscular de duchenne
WO2009049159A1 (fr)	2007-10-10	2009-04-16	Parion Sciences, Inc.	Administration d'osmolytes par canule nasale
SI2578571T1 (sl)	2007-11-16	2016-01-29	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
HRP20170241T2 (hr)	2007-12-07	2023-03-17	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
DK2615085T3 (en)	2008-03-31	2015-10-05	Vertex Pharma	Pyridyl derivatives as CFTR modulators
JP5369854B2 (ja)	2008-04-21	2013-12-18	住友化学株式会社	有害節足動物防除組成物および縮合複素環化合物
WO2009155017A2 (fr)	2008-05-30	2009-12-23	Merck & Co., Inc.	Nouveaux azabenzoxazoles substitués
TW201000099A (en)	2008-06-20	2010-01-01	Amgen Inc	S1P1 receptor agonists and use thereof
CN102076670B (zh) *	2008-06-24	2013-05-22	Irm责任有限公司	调节g蛋白偶联受体的化合物和方法
SG10201401169QA (en) *	2009-04-02	2014-05-29	Merck Serono Sa	Dihydroorotate dehydrogenase inhibitors
EP2467362A4 (fr)	2009-08-17	2013-06-26	Brigham & Womens Hospital	Inhibiteurs de protéine de transfert de la phosphatidylcholine
ES2533798T3 (es)	2009-10-12	2015-04-14	Bayer Cropscience Ag	1-(pirid-3-il)-pirazol y 1-(pirimid-5-il)- pirazol como agentes para combatir parásitos
US20130040983A1 (en) *	2010-01-08	2013-02-14	Jean-Michel Vernier	Raf kinase inhibitors
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ700556A (en)	2010-03-25	2016-04-29	Vertex Pharma	Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
RS54783B1 (sr)	2010-04-07	2016-10-31	Vertex Pharma	Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
CA2797118C (fr)	2010-04-22	2021-03-30	Vertex Pharmaceuticals Incorporated	Procede de production de composes de cycloalkylcarboxamido-indole
KR101799429B1 (ko) *	2010-05-03	2017-11-21	에스케이바이오팜 주식회사	신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
BR112013004443A8 (pt)	2010-08-23	2018-01-02	Vertex Pharma	composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas
CA2821992A1 (fr)	2010-10-01	2012-04-05	Moderna Therapeutics, Inc.	Synthese d'acides nucleiques et methodes d'utilisation associees
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
EP2717855A4 (fr)	2011-06-07	2014-11-12	Parion Sciences Inc	Procédés de traitement
US8945605B2 (en)	2011-06-07	2015-02-03	Parion Sciences, Inc.	Aerosol delivery systems, compositions and methods
AR086745A1 (es)	2011-06-27	2014-01-22	Parion Sciences Inc	3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2545964A1 (fr)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr)	2011-10-03	2022-04-29	Modernatx, Inc.	Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
MX357328B (es)	2011-11-08	2018-07-05	Vertex Pharma	Moduladores de trasportadores de casete enlazante de atp.
SI2791160T1 (sl)	2011-12-16	2022-07-29	Modernatx, Inc.	Sestave modificirane MRNA
SG10201606135TA (en)	2012-01-25	2016-09-29	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR101452235B1 (ko) *	2012-02-03	2014-10-22	서울대학교산학협력단	신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en)	2012-04-02	2014-10-30	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
HK1206612A1 (en)	2012-04-02	2016-01-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RS61664B1 (sr)	2012-04-24	2021-04-29	Vertex Pharma	Inhibitori dna-pk
LT2855435T (lt)	2012-05-29	2018-09-10	Parion Sciences, Inc.	Amino amidai, panašūs į dendrimerus, su natrio kanalų blokavimo aktyvumu, skirti gydyti sausų akių sindromą ir kitas gleivinių ligas
EP2872122A1 (fr)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
SMT202500078T1 (it)	2012-11-02	2025-03-12	Vertex Pharma	Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
SMT202200337T1 (it)	2012-11-26	2022-09-14	Modernatx Inc	Rna modificato al livello del terminale
ES2834959T3 (es)	2012-12-06	2021-06-21	Celgene Quanticel Res Inc	Inhibidores de histona desmetilasa
WO2014099673A1 (fr)	2012-12-17	2014-06-26	Parion Sciences, Inc.	Composés 3,5-diamino -6-chloro-n-(n- (4-phénylbutyl)carbamimidoyl) pyrazine-2-carboxamide
ES2674665T3 (es)	2012-12-17	2018-07-03	Parion Sciences, Inc.	Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
US9593084B2 (en)	2012-12-17	2017-03-14	Parion Sciences, Inc.	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
SI3527563T1 (sl)	2013-03-12	2022-01-31	Vertex Pharmaceuticals Incorporated	Inhibitorji DNA-PK
WO2014163934A1 (fr) *	2013-03-13	2014-10-09	Dow Agrosciences Llc	Préparation de 1,3-(diaryle- substitué)-1,2,4-triazoles
CA2903103C (fr)	2013-03-15	2020-06-09	Discoverybiomed, Inc.	Derives de coumarine et leurs methodes d'utilisation dans le traitement de la fibrose kystique, de la bronchopneumopathie chronique obstructive et des troubles lies a des proteine s mal repliees
UY35435A (es) *	2013-03-15	2014-10-31	Monsanto Technology Llc	?1,3,4-oxadiazol-2(3h)-onas 3,5-disustituidas y composiciones y métodos para controlar plagas de ne matodos?.
WO2014152278A2 (fr)	2013-03-15	2014-09-25	Discoverybiomed, Inc.	Dérivés de coumarine et méthodes d'utilisation dans le traitement de maladies hyperprolifératives
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en)	2013-10-03	2019-06-18	Modernatx, Inc.	Polynucleotides encoding low density lipoprotein receptor
FR3011468B1 (fr) *	2013-10-04	2015-12-04	Inventiva	Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
US9611263B2 (en)	2013-10-08	2017-04-04	Calcimedica, Inc.	Compounds that modulate intracellular calcium
SI3424920T1 (sl)	2013-10-17	2020-08-31	Vertex Pharmaceuticals Incorporated	Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
US9873677B2 (en)	2014-03-06	2018-01-23	Ptc Therapeutics, Inc.	Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
RS62140B1 (sr)	2014-04-15	2021-08-31	Vertex Pharma	Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
WO2016014846A1 (fr)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
IL313498A (en)	2014-10-06	2024-08-01	Vertex Pharma	Modulators of the cystic fibrosis transmembrane conductance regulator
US10710992B2 (en)	2014-12-01	2020-07-14	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
AU2015367531B2 (en) *	2014-12-17	2020-04-30	King's College London	Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists
ES2899757T3 (es) *	2014-12-19	2022-03-14	Galderma Res & Dev	Compuestos heterocíclicos, su procedimiento de síntesis y su uso en medicina así como en cosmética
US10328064B2 (en)	2014-12-23	2019-06-25	Fgh Biotech, Inc.	Compositions of fatostatin based heterocyclic compounds and uses thereof
WO2017016910A1 (fr) *	2015-07-24	2017-02-02	Syngenta Participations Ag	Dérivés de 1,2,4-triazole à activité pesticide comportant des substituants contenant du soufre
MX2018005361A (es)	2015-10-30	2018-06-07	Ptc Therapeutics Inc	Metodos para tratar epilepsia.
EP3393245A1 (fr)	2015-12-22	2018-10-31	Syngenta Participations AG	Dérivés de pyrazole à activité pesticide
CA3048193A1 (fr)	2015-12-23	2017-06-29	Moonshot Pharma Llc	Methodes pour induire une reponse immunitaire en activant la lecture de codons stop prematures
MX382630B (es)	2016-04-29	2025-03-13	Fgh Biotech Inc	Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
CA2968836C (fr)	2016-06-13	2025-09-02	Gilead Sciences, Inc.	Composes modulant fxr (nr1h4)
EP3468962A1 (fr)	2016-06-13	2019-04-17	Gilead Sciences, Inc.	Composés modulant le fxr (nr1h4)
GB201610867D0 (en)	2016-06-22	2016-08-03	King S College London	Crystalline forms of a therapeutic compound and processes for their preparation
EP3510027B1 (fr)	2016-09-07	2022-11-02	FGH BioTech, Inc.	Composés de pyrazole di-substitués pour le traitement de maladies
KR20190062485A (ko)	2016-09-27	2019-06-05	버텍스 파마슈티칼스 인코포레이티드	Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CN110072860B (zh) *	2016-12-20	2022-09-02	百时美施贵宝公司	可用作免疫调节剂的化合物
EP4424364A3 (fr)	2017-03-28	2024-11-27	Gilead Sciences, Inc.	Méthodes de traitement d'une maladie hépatique
US11439623B2 (en) *	2017-04-04	2022-09-13	Case Western Reserve University	Method of modulating ribonucleotide reductase
IL271149B2 (en) *	2017-06-14	2024-05-01	Trevena Inc	Compounds for modulating s1p1 activity and methods of using the same
WO2018232357A1 (fr)	2017-06-15	2018-12-20	Modernatx, Inc.	Formulations d'arn
JP2020525434A (ja)	2017-06-22	2020-08-27	ムーンショットファーマエルエルシー	アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
US11214567B2 (en) *	2017-08-23	2022-01-04	The Regents Of The University Of Michigan	Small molecule inhibitors of MYC and uses thereof
US11744801B2 (en)	2017-08-31	2023-09-05	Modernatx, Inc.	Methods of making lipid nanoparticles
WO2019101709A1 (fr)	2017-11-23	2019-05-31	Universita' Degli Studi Di Palermo	Dérivés d'oxadiazole pour le traitement de maladies génétiques causées par des mutations non-sens
WO2019124577A1 (fr) *	2017-12-20	2019-06-27	재단법인 경기도경제과학진흥원	Dérivé de triazole et utilisation associée
CN112074897B (zh) *	2018-03-29	2025-01-28	艾克斯普罗工程股份公司	用于产生高振幅的压力波的设备和方法
US12152242B2 (en)	2018-04-23	2024-11-26	The Curators Of The University Of Missouri	CRISPR therapy
WO2020061457A1 (fr)	2018-09-20	2020-03-26	Modernatx, Inc.	Préparation de nanoparticules lipidiques et leurs méthodes d'administration
AU2020209564B2 (en)	2019-01-15	2022-12-01	Gilead Sciences, Inc.	FXR (NR1H4) modulating compounds
CN118388474A (zh)	2019-02-19	2024-07-26	吉利德科学公司	Fxr激动剂的固体形式
JP2022527294A (ja) *	2019-03-26	2022-06-01	ニューロポアセラピーズインコーポレイテッド	Ｔｌｒシグナル伝達の調節剤としての化合物及び組成物
EP4015506A4 (fr) *	2019-09-25	2023-08-30	Korea Institute of Radiological & Medical Sciences	Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de trifluorométhylphényl pyrazole comme principe actif
KR102663365B1 (ko) *	2019-09-25	2024-05-08	한국원자력의학원	신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
JP2023502123A (ja)	2019-11-19	2023-01-20	トレベナ・インコーポレイテッド	Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法
US12486246B2 (en)	2019-12-10	2025-12-02	The Trustees Of Indiana University	Replication protein A (RPA)-DNA interaction inhibitors
KR102847693B1 (ko) *	2019-12-27	2025-08-18	서울대학교산학협력단	옥사디아졸 유도체를 포함하는 비만의 예방 또는 치료용 조성물
EP3912628A1 (fr)	2020-05-20	2021-11-24	Institut de Recherche en Semiochimie et Ethologie Appliquée	Analogues de nucléoside pour inhiber la protéase principale d'un coronavirus
CN117042759A (zh) *	2021-02-04	2023-11-10	国立大学法人九州大学	Il-31产生抑制剂和含有它的药物组合物
CN119350257B (zh) *	2021-06-28	2025-11-18	广西医科大学	三氮唑化合物
EP4173485A1 (fr) *	2021-10-27	2023-05-03	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Composés inhibant l'agrégation de protéine pour la lutte contre les maladies des plantes
CN119095831A (zh) *	2022-03-25	2024-12-06	瓦斯塞拉股份有限公司	3-苯基异噁唑衍生物和含有其作为活性成分的用于预防或治疗眼部疾病的药物组合物
EP4612139A1 (fr)	2022-11-03	2025-09-10	Sentonix, Inc.	Ligands sélectifs pour agrégats de protéine tau
GB202300021D0 (en) *	2023-01-03	2023-02-15	Thirtyfivebio Ltd	Compounds
WO2025116596A1 (fr) *	2023-11-29	2025-06-05	가천대학교 산학협력단	Nouveau composé et composition pour la prévention ou le traitement de maladies oculaires le contenant
CN119144004B (zh) *	2024-08-12	2025-10-28	兰州大学	一种m-hof材料及其制备方法和在氢氧根离子识别中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3153017A (en) *	1961-06-29	1964-10-13	Eastman Kodak Co	Nitrogen-containing linear polyesters from amino methyl cyclohexanol and dicarboxylic acids
CH522432A (de) *	1967-02-07	1972-06-30	Ciba Geigy Ag	Verwendung von v-Triazolen als Schutzmittel für nichttextile organische Substrate gegen UV-Strahlen
GB1263940A (en)	1968-08-02	1972-02-16	Innothera Lab Sa	0-phenyl-pyrroles
GB1248070A (en)	1968-12-16	1971-09-29	Science Union & Cie	Thiazolyl-benzoic acid derivatives and process for preparing them
US3803162A (en)	1969-10-03	1974-04-09	Sandoz Ltd	7-triazolyl-3-phenylcoumarins
US3679669A (en)	1970-09-23	1972-07-25	Ciba Geigy Ag	Phenyl-1,3,4-oxdiazole compounds
US3882138A (en) *	1971-08-09	1975-05-06	Uniroyal Inc	Oxazole and oxadiazole benzoic acid derivatives as herbicides
US3964896A (en) *	1971-08-09	1976-06-22	Uniroyal, Inc.	Oxadiazole benzoic acid derivatives as herbicides
BE789948A (fr)	1971-10-13	1973-04-11	Sandoz Sa	Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3948937A (en) *	1972-02-29	1976-04-06	E. I. Du Pont De Nemours And Company	Pyrazole plant growth regulants
US3947263A (en) *	1974-07-29	1976-03-30	Uniroyal, Inc.	Plant growth regulants
US4035175A (en)	1974-07-29	1977-07-12	Uniroyal Inc.	Method of retarding the growth of plants using certain oxadiazolyl, oxazolyl or thiadiazolyl benzoic acid derivatives
AU497898B2 (en) *	1975-01-10	1979-01-18	Commonwealth Scientific And Industrial Research Organisation	Plant growth regulating method and composition for use therein
US4038285A (en) *	1975-06-25	1977-07-26	E. I. Du Pont De Nemours And Company	1-(2-carboxyaryl)-4-arylimidazoles and 1-(2-carboxyaryl)-3-aryl-1,2,4-triazoles
US4032644A (en) *	1975-12-29	1977-06-28	Sandoz, Inc.	Isoxazolyl benzoic acids
DE2722331A1 (de) *	1976-05-18	1977-11-24	Ricoh Kk	1,3,4-oxadiazolderivate sowie diese enthaltende elektrophotographische aufzeichnungsmaterialien
US4135910A (en) *	1977-05-12	1979-01-23	Monsanto Company	Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) *	1977-05-12	1979-09-04	Monsanto Company	Oxadiazol-5-yl-benzoates
US4140515A (en) *	1977-05-12	1979-02-20	Monsanto Company	Aryl-3-isoxazole benzoates as plant growth regulants and herbicides
US4210762A (en) *	1978-08-17	1980-07-01	Monsanto Company	2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US4268299A (en) *	1978-08-17	1981-05-19	Monsanto Company	Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
CA1125768A (fr) *	1978-10-31	1982-06-15	Hoffmann-La Roche Limited	Derives de benzoxazole
US4229204A (en) *	1978-12-04	1980-10-21	Monsanto Company	Trifluoromethylphenyl isoxazolyl benzoates
JPS58177977A (ja)	1982-04-09	1983-10-18	Grelan Pharmaceut Co Ltd	４−フエニルピラゾ−ル類
SU1063100A1 (ru) *	1982-04-22	1985-06-30	Предприятие П/Я А-7850	Жидкокристаллический материал дл электрооптических устройств
US4760066A (en) *	1982-09-21	1988-07-26	Wayne State University	Method for treating human tumor cell metastasis
US4546113A (en) *	1983-04-14	1985-10-08	Pfizer Inc.	Antiprotozoal diamidines
DD226883A1 (de) *	1984-07-30	1985-09-04	Neubauer T Paedagog Hochschule	Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen
US5436252A (en) *	1986-12-19	1995-07-25	Merrell Dow Pharmaceuticals Inc.	5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5283187A (en)	1987-11-17	1994-02-01	Brown University Research Foundation	Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
DE3819037A1 (de) *	1988-06-04	1989-12-14	Hoechst Ag	2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
US5260451A (en) *	1989-05-11	1993-11-09	Merckle Gmbh	Substituted pyrrole compounds and use thereof in pharmaceutical compositions
US5022915A (en) *	1990-03-01	1991-06-11	Ici Americas Inc.	Substituted 2,4-diarylpyrimidines and their use as herbicides
CA2073981C (fr) *	1990-11-30	2002-01-08	Shiro Kondo	Derives de 2-arylthiazole et composition pharmaceutique a base de ces derives
FR2672050A1 (fr)	1991-01-30	1992-07-31	Atochem	Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese.
EP0646178A1 (fr)	1992-06-04	1995-04-05	The Regents Of The University Of California	Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
IL112290A (en) *	1994-01-12	1999-01-26	Novartis Ag	Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5521189A (en)	1994-05-06	1996-05-28	The University Of Nc At Ch	Methods of treating pneumocystis carinii pneumonia
US5486534A (en) *	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
RU2165423C2 (ru) *	1994-10-07	2001-04-20	Фудзисава Фармасьютикал Ко., Лтд.	Полипептидное соединение, способ его получения и фармацевтическая композиция
US5681746A (en)	1994-12-30	1997-10-28	Chiron Viagene, Inc.	Retroviral delivery of full length factor VIII
JP3964478B2 (ja) *	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
DE19536811A1 (de) *	1995-10-02	1997-04-03	Basf Ag	Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
KR100485642B1 (ko)	1996-03-18	2005-09-30	에자이 가부시키가이샤	축합고리함유카르복실산유도체
DE19620041A1 (de) *	1996-05-17	1998-01-29	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
TW467902B (en) *	1996-07-31	2001-12-11	Bristol Myers Squibb Co	Diphenyl heterocycles as potassium channel modulators
MY128323A (en) *	1996-09-30	2007-01-31	Otsuka Pharma Co Ltd	Thiazole derivatives for inhibition of cytokine production and of cell adhesion
WO1998015532A1 (fr)	1996-10-09	1998-04-16	Novartis Ag	Synthese en phase solide de composes heterocycliques
JP2001506601A (ja) *	1996-11-25	2001-05-22	ザプロクターアンドギャンブルカンパニー	α―２アドレナリン受容体作動薬として有用な２―イミダゾリニルアミノベンゾオキサゾール化合物
WO1998028421A1 (fr)	1996-12-20	1998-07-02	Human Genome Sciences, Inc.	Proteine i secretee induite par oncogene d'origine humaine
DK1023063T3 (da)	1997-10-06	2004-01-26	Abbott Gmbh & Co Kg	Indeno[1,2-c]-,naphtho[1,2-c]- og benzo[6,7]cyclohepta[1,2-c]pyrazolderivater
SI1023063T1 (en) *	1997-10-06	2004-02-29	Abbott Gmbh & Co. Kg	INDENO(1,2-c), NAPHTHO(1,2-c)- AND BENZO(6,7)CYCLOHEPTA(1,2-c)PYRAZOLE DERIVATIVES
IT1300055B1 (it)	1998-04-17	2000-04-05	Boehringer Ingelheim Italia	Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
BR9907967A (pt) *	1998-02-09	2000-10-17	Fujisawa Pharmaceutical Co	Composto de polipeptideo, processo para sua preparação, composição farmacêutica compreendendo dito composto, e seu uso.
AU4005299A (en) *	1998-05-19	1999-12-06	Regents Of The University Of California, The	Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
JP2002522425A (ja)	1998-08-07	2002-07-23	カイロンコーポレイション	エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
DE19904406A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Substituierte Pyrazolcarbonsäuren
DE19904389A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
PL356485A1 (en)	1999-12-16	2004-06-28	Schering Corporation	Substituted imidazole neuropeptide y y5 receptor antagonists
US7729756B2 (en)	2000-01-18	2010-06-01	Siemens Aktiengesellschaft	Measurement system for examining a section of tissue on a patient and the use of a measurement system of this type
US6800604B2 (en)	2000-02-11	2004-10-05	Genentech, Inc.	Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
US6605615B2 (en)	2000-03-01	2003-08-12	Tularik Inc.	Hydrazones and analogs as cholesterol lowering agents
IL152830A0 (en) *	2000-05-22	2003-06-24	Aventis Pharma Inc	Arylmethylamine derivatives for use as tryptase inhibitors
GB0012362D0 (en)	2000-05-22	2000-07-12	Aventis Pharma Ltd	Chemical compounds
WO2002036580A2 (fr) *	2000-10-31	2002-05-10	Lynn Bonham	Inhibiteurs benzoxazoles de lpaat-$g(b) et utilisations associees
PL369598A1 (en) *	2001-02-21	2005-05-02	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AUPR362001A0 (en)	2001-03-08	2001-04-05	Fujisawa Pharmaceutical Co., Ltd.	New compound
JP2003026663A (ja)	2001-05-09	2003-01-29	Takeda Chem Ind Ltd	アゾール化合物、その製造法および用途
CN1522251A (zh)	2001-05-09	2004-08-18	ס��ũҩ��ʽ��	唑化合物及其制备方法和应用
JP2003081832A (ja) *	2001-06-26	2003-03-19	Takeda Chem Ind Ltd	レチノイド関連受容体機能調節剤
US7223791B2 (en) *	2001-06-26	2007-05-29	Takeda Pharmaceutical Company Limited	Function regulator for retinoid relative receptor
DE10136066A1 (de) *	2001-07-25	2003-02-13	Bayer Cropscience Ag	Tetrahydropyridazin-Derivate
WO2003016280A1 (fr)	2001-08-13	2003-02-27	Lion Bioscience Ag	Composes liant le recepteur nucleaire nr1h4
JP2005532983A (ja) *	2001-09-26	2005-11-04	バイエル・フアーマシユーチカルズ・コーポレーシヨン	Ｃ１７，２０リアーゼ阻害剤としての３‐ピリジルもしくは４‐イソキノリニルチアゾール
ES2295441T3 (es)	2001-12-18	2008-04-16	MERCK & CO., INC.	Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
JP4299139B2 (ja) *	2001-12-18	2009-07-22	メルクエンドカムパニーインコーポレーテッド	代謝型グルタミン酸受容体−５のヘテロアリール置換トリアゾールモジュレータ
CA2470519C (fr) *	2001-12-21	2009-11-17	Merck & Co., Inc.	Modulateurs pyrrole a substitution heteroaryle du recepteur 5 metabotropique du glutamate
WO2003097047A1 (fr) *	2002-05-13	2003-11-27	Eli Lilly And Company	Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
CA2486097A1 (fr)	2002-05-15	2003-11-27	Janssen Pharmaceutica N.V.	3-aminopyrazoles tricycliques n-substitues comme inhibiteurs des recepteurs du pdfg
ATE548354T1 (de) *	2002-07-24	2012-03-15	Ptc Therapeutics Inc	Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
AU2003261237A1 (en)	2002-07-24	2004-02-09	Ptc Therapeutics, Inc.	Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004009533A1 (fr)	2002-07-24	2004-01-29	Ptc Therapeutics, Inc.	Composes d'acide acetylamino benzoique et leur utilisation pour la suppression de non-sens et le traitement de maladie
AU2003246979B8 (en)	2002-08-13	2009-08-06	Merck Sharp & Dohme Limited	Phenylpyridazine derivatives as ligands for GABA receptors
PA8578101A1 (es) *	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
ES2283811T3 (es) *	2002-09-09	2007-11-01	Amgen Inc.	Derivados de 1,2-dihidro-pirazol-3-ona y 3-alcoxi-1h-pirazol sustituidos 1,4,5- para la utilizacion como agentes reductores de tnf-alfa e interleukina en el tratamiento de inflamaciones.
WO2004046122A2 (fr) *	2002-11-16	2004-06-03	Oxford Glycosciences (Uk) Ltd	Derives d'acides de benzoxazole, de benzothiazole, et de benzimidazole pharmaceutiquement actifs
US20040176264A1 (en) *	2002-12-30	2004-09-09	The Procter & Gamble Company	Rinse aid composition containing water-soluble metal salt for use in automatic dishwashing for glassware corrosion protection
GB0303503D0 (en) *	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
EP1597251B1 (fr)	2003-02-20	2009-06-10	SmithKline Beecham Corporation	Composes de pyrimidine
US7320986B2 (en)	2003-03-07	2008-01-22	Abbott Labortories	Fused tri and tetra-cyclic pyrazole kinase inhibitors
US6992096B2 (en) *	2003-04-11	2006-01-31	Ptc Therapeutics, Inc.	1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US7226930B2 (en)	2003-04-18	2007-06-05	Memory Pharmaceutical Corporation	Phosphodiesterase 4 inhibitors
JP4942654B2 (ja)	2004-08-23	2012-05-30	イーライリリーアンドカンパニー	ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
WO2006044456A1 (fr) *	2004-10-13	2006-04-27	Ptc Therapeutics, Inc.	Composes de suppression de non-sens et procedes de leur utilisation
WO2007059356A2 (fr) *	2005-11-19	2007-05-24	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibiteurs de l'ubiquitine e1
EP2284154A1 (fr) *	2009-07-29	2011-02-16	Argon Pharma S.L.	Composés anti-tumoraux à base de 1,2-diphénylpyrrole et leur procédé de préparation

2005
- 2005-10-13 WO PCT/US2005/036673 patent/WO2006044456A1/fr not_active Ceased
- 2005-10-13 MX MX2007004487A patent/MX2007004487A/es unknown
- 2005-10-13 EP EP10185128.5A patent/EP2301536B1/fr not_active Expired - Lifetime
- 2005-10-13 WO PCT/US2005/037052 patent/WO2006044682A1/fr not_active Ceased
- 2005-10-13 BR BRPI0515995-4A patent/BRPI0515995A/pt not_active IP Right Cessation
- 2005-10-13 EP EP05807667A patent/EP1799659A1/fr not_active Withdrawn
- 2005-10-13 EP EP10185126.9A patent/EP2301538B1/fr not_active Expired - Lifetime
- 2005-10-13 AU AU2005295778A patent/AU2005295778A1/en not_active Abandoned
- 2005-10-13 KR KR1020077010767A patent/KR20070067201A/ko not_active Withdrawn
- 2005-10-13 CA CA002582885A patent/CA2582885A1/fr not_active Abandoned
- 2005-10-13 WO PCT/US2005/036762 patent/WO2006044503A2/fr not_active Ceased
- 2005-10-13 MX MX2007004479A patent/MX2007004479A/es unknown
- 2005-10-13 KR KR1020077010794A patent/KR20070065429A/ko not_active Withdrawn
- 2005-10-13 JP JP2007536865A patent/JP2008515990A/ja active Pending
- 2005-10-13 US US11/577,189 patent/US9315467B2/en active Active
- 2005-10-13 EP EP16163831.7A patent/EP3067053A1/fr not_active Withdrawn
- 2005-10-13 EP EP15168072.5A patent/EP2939674A1/fr not_active Withdrawn
- 2005-10-13 AU AU2005295730A patent/AU2005295730A1/en not_active Abandoned
- 2005-10-13 EP EP10185130.1A patent/EP2311455B1/fr not_active Expired - Lifetime
- 2005-10-13 WO PCT/US2005/036761 patent/WO2006044502A2/fr not_active Ceased
- 2005-10-13 MX MX2007004484A patent/MX2007004484A/es unknown
- 2005-10-13 SG SG200906829-7A patent/SG156641A1/en unknown
- 2005-10-13 EP EP10185139A patent/EP2402323A3/fr not_active Withdrawn
- 2005-10-13 EP EP05815159.8A patent/EP1815206B1/fr not_active Expired - Lifetime
- 2005-10-13 WO PCT/US2005/036764 patent/WO2006044505A2/fr not_active Ceased
- 2005-10-13 CA CA002583177A patent/CA2583177A1/fr not_active Abandoned
- 2005-10-13 JP JP2007536837A patent/JP2008515985A/ja active Pending
- 2005-10-13 KR KR1020077009154A patent/KR20070067165A/ko not_active Withdrawn
- 2005-10-13 JP JP2007536867A patent/JP2008515992A/ja active Pending
- 2005-10-13 US US11/577,192 patent/US7902235B2/en not_active Expired - Fee Related
- 2005-10-13 EP EP05804194A patent/EP1799207A2/fr not_active Withdrawn
- 2005-10-13 BR BRPI0516110-0A patent/BRPI0516110A/pt not_active IP Right Cessation
- 2005-10-13 CA CA002583976A patent/CA2583976A1/fr not_active Abandoned
- 2005-10-13 EP EP10185133A patent/EP2363129A1/fr not_active Withdrawn
- 2005-10-13 CA CA002583159A patent/CA2583159A1/fr not_active Abandoned
- 2005-10-13 US US11/577,177 patent/US9051342B2/en not_active Expired - Fee Related
- 2005-10-13 AU AU2005295727A patent/AU2005295727A1/en not_active Abandoned
- 2005-10-13 CA CA002583971A patent/CA2583971A1/fr not_active Abandoned
- 2005-10-13 US US11/577,176 patent/US20080269191A1/en not_active Abandoned
- 2005-10-13 EP EP10185137A patent/EP2316452A1/fr not_active Withdrawn
- 2005-10-13 SG SG200906828-9A patent/SG156640A1/en unknown
- 2005-10-13 US US11/577,191 patent/US9611230B2/en not_active Expired - Fee Related
- 2005-10-13 EP EP05804171A patent/EP1812071A2/fr not_active Withdrawn
- 2005-10-13 EP EP05807462A patent/EP1799212A2/fr not_active Withdrawn
2007
- 2007-04-11 IL IL182464A patent/IL182464A0/en unknown
- 2007-04-11 IL IL182461A patent/IL182461A0/en unknown
- 2007-04-11 IL IL182459A patent/IL182459A0/en unknown
2011
- 2011-03-07 US US13/042,456 patent/US8710031B2/en not_active Expired - Fee Related
2014
- 2014-04-28 US US14/263,478 patent/US9273076B2/en not_active Expired - Lifetime
2015
- 2015-06-08 US US14/733,615 patent/US20150274674A1/en not_active Abandoned
2016
- 2016-04-15 US US15/130,318 patent/US20160229818A1/en not_active Abandoned
2017
- 2017-03-31 US US15/475,240 patent/US20170204073A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2007004479A (es)	2007-06-18
AU2005295778A1 (en)	2006-04-27
EP1815206B1 (fr)	2016-04-06
US20090203752A1 (en)	2009-08-13
EP1799659A1 (fr)	2007-06-27
JP2008515990A (ja)	2008-05-15
EP2301536A1 (fr)	2011-03-30
AU2005295730A1 (en)	2006-04-27
US20090253699A1 (en)	2009-10-08
WO2006044502A3 (fr)	2006-08-03
JP2008515985A (ja)	2008-05-15
WO2006044505A3 (fr)	2006-07-06
EP1799207A2 (fr)	2007-06-27
US20110160164A1 (en)	2011-06-30
US20150274674A1 (en)	2015-10-01
EP1799212A2 (fr)	2007-06-27
US20140235586A1 (en)	2014-08-21
AU2005295727A1 (en)	2006-04-27
EP2301538A1 (fr)	2011-03-30
KR20070067201A (ko)	2007-06-27
US8710031B2 (en)	2014-04-29
EP2363129A1 (fr)	2011-09-07
US9611230B2 (en)	2017-04-04
WO2006044505A2 (fr)	2006-04-27
US20170204073A1 (en)	2017-07-20
US9315467B2 (en)	2016-04-19
JP2008515992A (ja)	2008-05-15
EP2402323A2 (fr)	2012-01-04
KR20070067165A (ko)	2007-06-27
MX2007004484A (es)	2007-06-25
EP3067053A1 (fr)	2016-09-14
WO2006044682A1 (fr)	2006-04-27
EP1812071A2 (fr)	2007-08-01
WO2006044502A2 (fr)	2006-04-27
WO2006044503A2 (fr)	2006-04-27
BRPI0515995A (pt)	2008-08-19
CA2583976A1 (fr)	2006-04-27
CA2583159A1 (fr)	2006-04-27
EP2402323A3 (fr)	2012-05-30
EP2939674A1 (fr)	2015-11-04
MX2007004487A (es)	2007-06-18
EP2316452A1 (fr)	2011-05-04
CA2583177A1 (fr)	2006-04-27
IL182464A0 (en)	2008-04-13
WO2006044456A1 (fr)	2006-04-27
US20160229818A1 (en)	2016-08-11
US20080280869A1 (en)	2008-11-13
EP2301538B1 (fr)	2015-05-20
CA2583971A1 (fr)	2006-04-27
US20080119473A1 (en)	2008-05-22
EP2311455B1 (fr)	2015-07-15
US7902235B2 (en)	2011-03-08
EP2301536B1 (fr)	2014-04-09
WO2006044503A3 (fr)	2006-07-06
US20080269191A1 (en)	2008-10-30
IL182459A0 (en)	2007-07-24
EP2311455A1 (fr)	2011-04-20
US9273076B2 (en)	2016-03-01
EP1815206A1 (fr)	2007-08-08
US9051342B2 (en)	2015-06-09
IL182461A0 (en)	2007-10-31
BRPI0516110A (pt)	2008-08-26
SG156640A1 (en)	2009-11-26
KR20070065429A (ko)	2007-06-22
CA2582885A1 (fr)	2006-04-27

Publication	Publication Date	Title
SG156641A1 (en)	2009-11-26	Compounds for nonsense suppression, and methods for their use
HUS2100051I1 (hu)	2021-12-28	Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
SI1742644T1 (sl)	2012-03-30	Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
UA95310C2 (ru)	2011-07-25	Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
MX2008011633A (es)	2008-12-16	Aminoquinolonas como inhibidores de gsk-3.
MX2009000285A (es)	2009-06-08	Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
PT1984357E (pt)	2013-12-23	Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TN2010000122A1 (en)	2011-09-26	Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl)	2011-03-31	Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
ZA200807879B (en)	2009-12-30	Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2005004818A3 (fr)	2005-05-06	Composes heterocycliques et leur utilisation comme agents anticancereux
MY191349A (en)	2022-06-17	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2004009610A3 (fr)	2005-10-06	Utilisation de composes nucleosidiques pour la suppression non-sens et le traitement de maladies genetiques
UA94909C2 (ru)	2011-06-25	Фармацевтическая композиция нейроактивного стероида и ее применение
WO2010059004A3 (fr)	2010-09-10	Composé pouvant empêcher la liaison p53-snail, et agent thérapeutique contre le cancer contenant ce composé en tant que principe actif
WO2010121164A3 (fr)	2011-02-24	Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
MX2010002667A (es)	2010-04-01	Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
MXPA05013016A (es)	2006-03-02	Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
WO2007130501A3 (fr)	2008-01-17	Polythérapie pour traiter le cancer
TW200716088A (en)	2007-05-01	Formulations and methods for treating amyloidosis
WO2006096759A3 (fr)	2007-04-05	Methodes et compositions destinees a traiter le cancer
WO2006078336A3 (fr)	2006-11-30	Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
MX2010003615A (es)	2010-06-09	Tratamiento de desordenes neurologicos.
TW200603792A (en)	2006-02-01	Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors